CYTR Share Price

Open 0.32 Change Price %
High 0.37 1 Day 0.03 9.09
Low 0.32 1 Week 0.00 0.00
Close 0.36 1 Month -0.03 -7.69
Volume 2458632 1 Year -0.16 -30.77
52 Week High 1.00
52 Week Low 0.31
CYTR Important Levels
Resistance 2 0.41
Resistance 1 0.39
Pivot 0.35
Support 1 0.33
Support 2 0.31
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

CytRx Corporation (NASDAQ: CYTR)

CYTR Technical Analysis 5
As on 31st Oct 2017 CYTR Share Price closed @ 0.36 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.50 & Strong Sell for SHORT-TERM with Stoploss of 0.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTR Target for November
1st Target up-side 0.46
2nd Target up-side 0.53
3rd Target up-side 0.6
1st Target down-side 0.26
2nd Target down-side 0.19
3rd Target down-side 0.12
CYTR Other Details
Segment EQ
Market Capital 47314736.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytrx.com
CYTR Address
CYTR
11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
CYTR Latest News
Interactive Technical Analysis Chart CytRx Corporation ( CYTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CytRx Corporation
CYTR Business Profile
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.